Quest Diagnostics (DGX) Stock Chart - Revenue & Earnings | Quarter Chart
Revenue by Product
Revenue by Geography
Revenue, Gross Profit, Operating and Net Income
Margin (%)
Operating Expenses
EBITDA
EPS
Revenue Variation (%)
Income Variation (%)
Revenue YoY Variation (%)
Income YoY Variation (%)
Price-to-Earning Ratio
Income Breakdown
Per Share Metrics
Expense Ratios
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt Ratio
Current Ratio
Quick Ratio
Cash & Equivalents
Total Assets
Total Liabilities
Shareholders Equity
Asset Composition
Debt Structure
Quest Diagnostics (DGX) quarterly earnings & revenue
Quest Diagnostics (DGX) reported revenue of $2.90B for Q1 2026, up 9.2% year-over-year, with net income of $252.00M and diluted EPS of $2.24.
Over the last four reported quarters, Quest Diagnostics generated $11.28B in revenue and $1.02B in net income.
Quest Diagnostics's next earnings report is scheduled for July 23, 2026 before market open; analysts estimate EPS of $2.81.
Quest Diagnostics quarterly results
| Fiscal quarter | Revenue | Revenue YoY | Net income | EPS (diluted) |
|---|---|---|---|---|
| Q1 2026 | $2.90B | +9.2% | $252.00M | $2.24 |
| Q4 2025 | $2.81B | +7.1% | $245.00M | $2.18 |
| Q3 2025 | $2.82B | +13.2% | $245.00M | $2.16 |
| Q2 2025 | $2.76B | +15.2% | $282.00M | $2.47 |
| Q1 2025 | $2.65B | +12.1% | $220.00M | $1.94 |
| Q4 2024 | $2.62B | +14.6% | $222.00M | $1.95 |
| Q3 2024 | $2.49B | +8.4% | $226.00M | $1.99 |
| Q2 2024 | $2.40B | +2.5% | $229.00M | $2.04 |
Quest Diagnostics (DGX) — frequently asked questions
When does Quest Diagnostics (DGX) report earnings next?
Quest Diagnostics is expected to report earnings on July 23, 2026 before market open. Analysts estimate EPS of $2.81.
What was DGX's revenue last quarter?
Quest Diagnostics reported revenue of $2.90B in Q1 2026, up 9.2% from the same quarter a year earlier.
What was DGX's EPS last quarter?
Quest Diagnostics reported diluted EPS of $2.24 in Q1 2026.
Is Quest Diagnostics profitable?
Quest Diagnostics is currently profitable, with $1.02B in net income over the last four reported quarters.
Compare with other Healthcare companies: Eli Lilly (LLY) · Johnson & Johnson (JNJ) · AbbVie (ABBV) · UnitedHealth (UNH) · Roche (ROG.SW) · Merck (MRK)